Hikma’s all three segments continued their healthy performance in Q3. While the management upgraded its 2023 guidance for two segments, Injectables was held back by temporary capacity constraints, which led to this segment’s lower-than-expected performance in Q3 and a slight downward revision to the full-year outlook. Nonetheless, the Injectables’ situation is expected to normalise in 2024. Overall, the strong ongoing momentum, the promising long-term prospects for generics/biosimilars and a hea ....